Literature DB >> 36175804

The natural medicinal fungus Huaier promotes the anti-hepatoma efficacy of sorafenib through the mammalian target of rapamycin-mediated autophagic cell death.

Zhengguang Zhang1, Cunsi Shen2, Fuqiong Zhou3.   

Abstract

Sorafenib (SOR) is currently the first line molecular targeting agent for advanced liver cancer therapy. Unfortunately, the insensitivity of liver cancer patients to SOR relatively limits its effectiveness. Huaier (HUA), a natural medicinal parasitic fungus found on the Sophora japonica Linn., has been widely employed as an adjuvant medication for numerous malignancies due to its potent anti-tumoral properties. This study aims to elucidate the enhancing therapeutic efficacy of HUA on SOR treatment in hepatocellular carcinoma (HCC) cells and mouse models. The CCK-8, clone formation, flow cytometry, immunofluorescence, transmission electron microscopy, western blot, bioinformatic analysis, and xenograft tumor assays were performed to evaluate the synergistic anti-hepatoma efficacy and mechanisms of HUA-SOR combination treatment on HCC cells. The results revealed combination treatment further inhibited proliferation, promoted apoptosis, enhanced autophagy of HCC cells, and suppressed the growth of transplanted tumors in mice, compared with either HUA or SOR treatment alone. For Hep3B and Huh7 cells, the optimal synergistic doses of HUA in combination with SOR were 8 mg/mL + 4 μM and 4 mg/mL + 2 μM, with combination index values of 0.646 and 0.588, respectively. Additionally, the underlying mechanisms might be related to biological processes that are mediated by mammalian target of rapamycin (mTOR). The combination treatment downregulated the protein expression levels of p-mTOR, p-p70S6K, p62, and upregulated the protein expression levels of Beclin-1 and LC3B-II. The mTOR activator MHY1485 attenuated the effect of HUA-SOR combination by inhibiting autophagy, suggesting HUA may potentiate the sensitivity of HCC cells to SOR by partially inducing mTOR-mediated autophagic cell death. These findings might provide a rationale experimental foundation for clinical applications of HUA with SOR.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Autophagic cell death; Hepatocellular carcinoma; Huaier; Sorafenib

Mesh:

Substances:

Year:  2022        PMID: 36175804     DOI: 10.1007/s12032-022-01797-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.738


  5 in total

1.  Huaier suppresses proliferative and metastatic potential of prostate cancer PC3 cells via downregulation of Lamin B1 and induction of autophagy.

Authors:  Ailin Yang; Yanan Zhao; Ying Wang; Xiaojun Zha; Yunfang Zhao; Pengfei Tu; Zhongdong Hu
Journal:  Oncol Rep       Date:  2018-04-05       Impact factor: 3.906

Review 2.  [Research progress on anti-tumor effect of Huaier].

Authors:  Ai-lin Yang; Zhong-dong Hu; Peng-fei Tu
Journal:  Zhongguo Zhong Yao Za Zhi       Date:  2015-12

3.  Scintigraphic Imaging of Neovascularization With 99mTc-3PRGD2 for Evaluating Early Response to Endostar Involved Therapies on Pancreatic Cancer Xenografts In Vivo.

Authors:  Xiaona Jin; Chengyan Dong; Kun Zheng; Ximin Shi; Yu Liu; Li Huo; Fan Wang; Fang Li
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 5.738

4.  Serotonergic dysfunctions and abnormal iron metabolism: Relevant to mental fatigue of Parkinson disease.

Authors:  Li-Jun Zuo; Shu-Yang Yu; Yang Hu; Fang Wang; Ying-Shan Piao; Teng-Hong Lian; Qiu-Jin Yu; Rui-Dan Wang; Li-Xia Li; Peng Guo; Yang Du; Rong-Yan Zhu; Zhao Jin; Ya-Jie Wang; Xiao-Min Wang; Piu Chan; Sheng-Di Chen; Yong-Jun Wang; Wei Zhang
Journal:  Sci Rep       Date:  2016-12-21       Impact factor: 4.379

5.  Genetic Polymorphisms and Platinum-Based Chemotherapy-Induced Toxicities in Patients With Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Wenhui Liu; Ying Wang; Jianquan Luo; Haiyan Yuan; Zhiying Luo
Journal:  Front Oncol       Date:  2020-03-17       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.